El ekzaması tedavisinde yeni bir seçenek: topikal pimekrolimus

Meslek dermatozlar> aras>nda en s>k görülen tablo el ekzemalar>d>r. El ekzemalar>n>n kronik ve tekrarlay>c> seyrinden dolay> tedavisi hem hasta hem de hekim için sorun teflkil etmektedir. Topikal kortikosteroidlerin uzun süreli ku...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Türkderm 2007, Vol.41 (4), p.125-128
Hauptverfasser: BAŞKAN, Emel, Bülbül, KAÇAR, Seval, Doğruk, TUNALI, Şükran, TURAN, Ayşegül
Format: Artikel
Sprache:tur
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 128
container_issue 4
container_start_page 125
container_title Türkderm
container_volume 41
creator BAŞKAN, Emel, Bülbül
KAÇAR, Seval, Doğruk
TUNALI, Şükran
TURAN, Ayşegül
description Meslek dermatozlar> aras>nda en s>k görülen tablo el ekzemalar>d>r. El ekzemalar>n>n kronik ve tekrarlay>c> seyrinden dolay> tedavisi hem hasta hem de hekim için sorun teflkil etmektedir. Topikal kortikosteroidlerin uzun süreli kullan>mlar>na ba¤l> yan etkilerinden dolay> yeni tedavi aray>fllar> do¤mufltur. Bu çal>flmam>zda askomisin türevi olan ve atopik dermatit tedavisinde güvenle kullan>lan topikal pimekrolimus %1 kremin el ekzemas> tedavisindeki etkinli¤ini de¤erlendirmeyi amaçlad>k. Gereç ve Yöntem: Plasebo kontrollü, randomize çal>flmam>zda bilateral el ekzemas> olan toplam 25 hastan>n her bir eline plasebo ve di¤er taraf>na pimekrolimus %1 krem uygulat>ld>. Çal>flman>n 2., 4., 6. ve 8. haftalar>nda tedaviye cevap klinik olarak de¤erlendirildi. Klinik de¤erlendirmede eritem, deskuamasyon, likenifikasyon, ödem, vezikülasyon, fissür oluflumu 0-4 aras>nda skorland>. Ayr>ca hastalar>n kafl>nt> de¤erlendirmesinde ayn> skorlama kullan>ld>. Tedavi s>ras>nda görülen yan etkiler de kay>t edildi. Hastalar 8 haftal>k tedavi dönemini takiben yaklafl>k 8 hafta süresince tedavisiz izlendi. Bulgular: Tedaviyi tamamlayan 9 erkek, 15 kad>n hastan>n yafllar> 18 - 63 aras>nda (ortalama yafl 35.79) de¤ifliyordu. Meslek gruplar> incelendi¤inde 14'ü ev han>m>, 4'ü sa¤l>k personeli, 3'ü ö¤retmen, 1'i polis, 1'i çiftçi ve 1'i tuhafiye malzemeleri imalatç>s> olarak de¤ifliyordu. Hastal>k süreleri 6 ay-20 y>l (ortalama 4.9 y>l) aras>nda idi. On üç hastada iritan kontakt dermatit, 11 hastada allerjik kontakt dermatit tan>s> saptand>. Pimekrolimus %1 krem hastalar taraf>ndan iyi tolere edilmifl ve hiçbir yan etki gözlenmemifltir. Tedavi sonu ilaç uygulanan ele ait toplam klinik skorlar plasebo uygulanan ele ait skorlar ile karfl>laflt>r>ld>¤>nda anlaml> bir azalma saptanm>flt>r (p=0.04). Sonuç: Sonuç olarak el ekzemalar>n>n tedavisinde topikal pimekrolimusun vezikülasyon d>fl>ndaki tüm belirtileri bask>lamada oldukça etkili, ribaund ve tafliflaksiye neden olmayan, kullan>m> kolay bir tedavi seçene¤i olabilece¤i sonucuna var>lm>flt>r. (Türkderm 2007; 41: 125-8) Hand eczema is the most common form of occupational dermatoses. Because of chronic and relapsing course, therapy is a problem for both physician and patient. New treatment alternati
format Article
fullrecord <record><control><sourceid>ulakbim</sourceid><recordid>TN_cdi_ulakbim_primary_82831</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>82831</sourcerecordid><originalsourceid>FETCH-ulakbim_primary_828313</originalsourceid><addsrcrecordid>eNpjYeA0NDC01DUyNIngYOAqLs4yMDAztrQ052RwcM1RSM2uSsxNLD6yUaEkNSWxLLM4My8lVaEyNS9TISmzSKE49fDy1LzUbCuFkvyCzOzEHIWCzNzU7KL8nMzc0mIeBta0xJziVF4ozc0g4-Ya4uyhW5qTmJ2UmRtfUJSZm1hUGW9hZGFsaExAGgCWXzYv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>El ekzaması tedavisinde yeni bir seçenek: topikal pimekrolimus</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>BAŞKAN, Emel, Bülbül ; KAÇAR, Seval, Doğruk ; TUNALI, Şükran ; TURAN, Ayşegül</creator><creatorcontrib>BAŞKAN, Emel, Bülbül ; KAÇAR, Seval, Doğruk ; TUNALI, Şükran ; TURAN, Ayşegül</creatorcontrib><description><![CDATA[Meslek dermatozlar&gt; aras&gt;nda en s&gt;k görülen tablo el ekzemalar&gt;d&gt;r. El ekzemalar&gt;n&gt;n kronik ve tekrarlay&gt;c&gt; seyrinden dolay&gt; tedavisi hem hasta hem de hekim için sorun teflkil etmektedir. Topikal kortikosteroidlerin uzun süreli kullan&gt;mlar&gt;na ba¤l&gt; yan etkilerinden dolay&gt; yeni tedavi aray&gt;fllar&gt; do¤mufltur. Bu çal&gt;flmam&gt;zda askomisin türevi olan ve atopik dermatit tedavisinde güvenle kullan&gt;lan topikal pimekrolimus %1 kremin el ekzemas&gt; tedavisindeki etkinli¤ini de¤erlendirmeyi amaçlad&gt;k. Gereç ve Yöntem: Plasebo kontrollü, randomize çal&gt;flmam&gt;zda bilateral el ekzemas&gt; olan toplam 25 hastan&gt;n her bir eline plasebo ve di¤er taraf&gt;na pimekrolimus %1 krem uygulat&gt;ld&gt;. Çal&gt;flman&gt;n 2., 4., 6. ve 8. haftalar&gt;nda tedaviye cevap klinik olarak de¤erlendirildi. Klinik de¤erlendirmede eritem, deskuamasyon, likenifikasyon, ödem, vezikülasyon, fissür oluflumu 0-4 aras&gt;nda skorland&gt;. Ayr&gt;ca hastalar&gt;n kafl&gt;nt&gt; de¤erlendirmesinde ayn&gt; skorlama kullan&gt;ld&gt;. Tedavi s&gt;ras&gt;nda görülen yan etkiler de kay&gt;t edildi. Hastalar 8 haftal&gt;k tedavi dönemini takiben yaklafl&gt;k 8 hafta süresince tedavisiz izlendi. Bulgular: Tedaviyi tamamlayan 9 erkek, 15 kad&gt;n hastan&gt;n yafllar&gt; 18 - 63 aras&gt;nda (ortalama yafl 35.79) de¤ifliyordu. Meslek gruplar&gt; incelendi¤inde 14'ü ev han&gt;m&gt;, 4'ü sa¤l&gt;k personeli, 3'ü ö¤retmen, 1'i polis, 1'i çiftçi ve 1'i tuhafiye malzemeleri imalatç&gt;s&gt; olarak de¤ifliyordu. Hastal&gt;k süreleri 6 ay-20 y&gt;l (ortalama 4.9 y&gt;l) aras&gt;nda idi. On üç hastada iritan kontakt dermatit, 11 hastada allerjik kontakt dermatit tan&gt;s&gt; saptand&gt;. Pimekrolimus %1 krem hastalar taraf&gt;ndan iyi tolere edilmifl ve hiçbir yan etki gözlenmemifltir. Tedavi sonu ilaç uygulanan ele ait toplam klinik skorlar plasebo uygulanan ele ait skorlar ile karfl&gt;laflt&gt;r&gt;ld&gt;¤&gt;nda anlaml&gt; bir azalma saptanm&gt;flt&gt;r (p=0.04). Sonuç: Sonuç olarak el ekzemalar&gt;n&gt;n tedavisinde topikal pimekrolimusun vezikülasyon d&gt;fl&gt;ndaki tüm belirtileri bask&gt;lamada oldukça etkili, ribaund ve tafliflaksiye neden olmayan, kullan&gt;m&gt; kolay bir tedavi seçene¤i olabilece¤i sonucuna var&gt;lm&gt;flt&gt;r. (Türkderm 2007; 41: 125-8) Hand eczema is the most common form of occupational dermatoses. Because of chronic and relapsing course, therapy is a problem for both physician and patient. New treatment alternatives have been investigated because of side effects of long-term topical corticosteroids use. In this study, we aimed to evaluate the efficacy of pimecrolimus 1% cream, an ascomisin derivative successfully used for atopic dermatitis, in the treatment of hand eczema. Material and Method: In this placebo-controlled, randomized study, pimecrolimus 1% cream was applied on one hand and placebo on the other hand of 25 patients twice daily for 8 weeks. Response to the therapy was assessed clinically at 2., 4., 6. and 8. weeks of the therapy. In the clinical assessment, erythema, desquamation, lichenification, edema, vesiculation and fissuring were scored between 0-4. Same scoring system was used also for the pruritus symptom of the patients. Side effects during the therapy were also recorded. The patients were followed for 8 additional weeks after the end of the therapy. Results: Nine male and 15 female patients with ages ranging from 18 to 63 (mean 35.79) completed the study. Of the patients, 14 were housewives, 4 were health workers, 3 were teachers, 1 was policeman, 1 was farmer and 1 was a haberdasher. The duration of disease ranged between 6 months and 20 years (mean 4.9 years). Diagnosis of irritant contact dermatitis was made in 13 patients and allergic contact dermatitis in 11 patients. Pimecrolimus 1% cream was well tolerated in all patients and no side effect was observed. The clinical score of pimecrolimus-applied hand improved significantly when compared with placebo applied hand (p=0.04). Conclusion: It is concluded that topical pimecrolimus cream appears to be an effective and easily appliable treatment alternative for all manifestations of hand eczema except for vesiculation, without any rebound and tachyphylaxis. (Turkderm 2007; 41: 125-8)]]></description><identifier>ISSN: 1019-214X</identifier><language>tur</language><publisher>Deri ve Zührevi Hastalıkları Derneği</publisher><subject>Administration, Topical ; Deri ve bağ dokusu hastalıkları ; Drug Therapy ; Eczema ; Egzema ; El ; El dermatozları ; Hand ; Hand Dermatoses ; İlaç tedavisi ; İlaç uygulama, topikal ; pimecrolimus ; pimekrolimus ; Skin and connective tissue diseases ; Terapötik ; Therapeutics</subject><ispartof>Türkderm, 2007, Vol.41 (4), p.125-128</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,4025</link.rule.ids></links><search><creatorcontrib>BAŞKAN, Emel, Bülbül</creatorcontrib><creatorcontrib>KAÇAR, Seval, Doğruk</creatorcontrib><creatorcontrib>TUNALI, Şükran</creatorcontrib><creatorcontrib>TURAN, Ayşegül</creatorcontrib><title>El ekzaması tedavisinde yeni bir seçenek: topikal pimekrolimus</title><title>Türkderm</title><description><![CDATA[Meslek dermatozlar&gt; aras&gt;nda en s&gt;k görülen tablo el ekzemalar&gt;d&gt;r. El ekzemalar&gt;n&gt;n kronik ve tekrarlay&gt;c&gt; seyrinden dolay&gt; tedavisi hem hasta hem de hekim için sorun teflkil etmektedir. Topikal kortikosteroidlerin uzun süreli kullan&gt;mlar&gt;na ba¤l&gt; yan etkilerinden dolay&gt; yeni tedavi aray&gt;fllar&gt; do¤mufltur. Bu çal&gt;flmam&gt;zda askomisin türevi olan ve atopik dermatit tedavisinde güvenle kullan&gt;lan topikal pimekrolimus %1 kremin el ekzemas&gt; tedavisindeki etkinli¤ini de¤erlendirmeyi amaçlad&gt;k. Gereç ve Yöntem: Plasebo kontrollü, randomize çal&gt;flmam&gt;zda bilateral el ekzemas&gt; olan toplam 25 hastan&gt;n her bir eline plasebo ve di¤er taraf&gt;na pimekrolimus %1 krem uygulat&gt;ld&gt;. Çal&gt;flman&gt;n 2., 4., 6. ve 8. haftalar&gt;nda tedaviye cevap klinik olarak de¤erlendirildi. Klinik de¤erlendirmede eritem, deskuamasyon, likenifikasyon, ödem, vezikülasyon, fissür oluflumu 0-4 aras&gt;nda skorland&gt;. Ayr&gt;ca hastalar&gt;n kafl&gt;nt&gt; de¤erlendirmesinde ayn&gt; skorlama kullan&gt;ld&gt;. Tedavi s&gt;ras&gt;nda görülen yan etkiler de kay&gt;t edildi. Hastalar 8 haftal&gt;k tedavi dönemini takiben yaklafl&gt;k 8 hafta süresince tedavisiz izlendi. Bulgular: Tedaviyi tamamlayan 9 erkek, 15 kad&gt;n hastan&gt;n yafllar&gt; 18 - 63 aras&gt;nda (ortalama yafl 35.79) de¤ifliyordu. Meslek gruplar&gt; incelendi¤inde 14'ü ev han&gt;m&gt;, 4'ü sa¤l&gt;k personeli, 3'ü ö¤retmen, 1'i polis, 1'i çiftçi ve 1'i tuhafiye malzemeleri imalatç&gt;s&gt; olarak de¤ifliyordu. Hastal&gt;k süreleri 6 ay-20 y&gt;l (ortalama 4.9 y&gt;l) aras&gt;nda idi. On üç hastada iritan kontakt dermatit, 11 hastada allerjik kontakt dermatit tan&gt;s&gt; saptand&gt;. Pimekrolimus %1 krem hastalar taraf&gt;ndan iyi tolere edilmifl ve hiçbir yan etki gözlenmemifltir. Tedavi sonu ilaç uygulanan ele ait toplam klinik skorlar plasebo uygulanan ele ait skorlar ile karfl&gt;laflt&gt;r&gt;ld&gt;¤&gt;nda anlaml&gt; bir azalma saptanm&gt;flt&gt;r (p=0.04). Sonuç: Sonuç olarak el ekzemalar&gt;n&gt;n tedavisinde topikal pimekrolimusun vezikülasyon d&gt;fl&gt;ndaki tüm belirtileri bask&gt;lamada oldukça etkili, ribaund ve tafliflaksiye neden olmayan, kullan&gt;m&gt; kolay bir tedavi seçene¤i olabilece¤i sonucuna var&gt;lm&gt;flt&gt;r. (Türkderm 2007; 41: 125-8) Hand eczema is the most common form of occupational dermatoses. Because of chronic and relapsing course, therapy is a problem for both physician and patient. New treatment alternatives have been investigated because of side effects of long-term topical corticosteroids use. In this study, we aimed to evaluate the efficacy of pimecrolimus 1% cream, an ascomisin derivative successfully used for atopic dermatitis, in the treatment of hand eczema. Material and Method: In this placebo-controlled, randomized study, pimecrolimus 1% cream was applied on one hand and placebo on the other hand of 25 patients twice daily for 8 weeks. Response to the therapy was assessed clinically at 2., 4., 6. and 8. weeks of the therapy. In the clinical assessment, erythema, desquamation, lichenification, edema, vesiculation and fissuring were scored between 0-4. Same scoring system was used also for the pruritus symptom of the patients. Side effects during the therapy were also recorded. The patients were followed for 8 additional weeks after the end of the therapy. Results: Nine male and 15 female patients with ages ranging from 18 to 63 (mean 35.79) completed the study. Of the patients, 14 were housewives, 4 were health workers, 3 were teachers, 1 was policeman, 1 was farmer and 1 was a haberdasher. The duration of disease ranged between 6 months and 20 years (mean 4.9 years). Diagnosis of irritant contact dermatitis was made in 13 patients and allergic contact dermatitis in 11 patients. Pimecrolimus 1% cream was well tolerated in all patients and no side effect was observed. The clinical score of pimecrolimus-applied hand improved significantly when compared with placebo applied hand (p=0.04). Conclusion: It is concluded that topical pimecrolimus cream appears to be an effective and easily appliable treatment alternative for all manifestations of hand eczema except for vesiculation, without any rebound and tachyphylaxis. (Turkderm 2007; 41: 125-8)]]></description><subject>Administration, Topical</subject><subject>Deri ve bağ dokusu hastalıkları</subject><subject>Drug Therapy</subject><subject>Eczema</subject><subject>Egzema</subject><subject>El</subject><subject>El dermatozları</subject><subject>Hand</subject><subject>Hand Dermatoses</subject><subject>İlaç tedavisi</subject><subject>İlaç uygulama, topikal</subject><subject>pimecrolimus</subject><subject>pimekrolimus</subject><subject>Skin and connective tissue diseases</subject><subject>Terapötik</subject><subject>Therapeutics</subject><issn>1019-214X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNpjYeA0NDC01DUyNIngYOAqLs4yMDAztrQ052RwcM1RSM2uSsxNLD6yUaEkNSWxLLM4My8lVaEyNS9TISmzSKE49fDy1LzUbCuFkvyCzOzEHIWCzNzU7KL8nMzc0mIeBta0xJziVF4ozc0g4-Ya4uyhW5qTmJ2UmRtfUJSZm1hUGW9hZGFsaExAGgCWXzYv</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>BAŞKAN, Emel, Bülbül</creator><creator>KAÇAR, Seval, Doğruk</creator><creator>TUNALI, Şükran</creator><creator>TURAN, Ayşegül</creator><general>Deri ve Zührevi Hastalıkları Derneği</general><scope>GIY</scope><scope>GIZ</scope><scope>GJA</scope><scope>GJB</scope></search><sort><creationdate>2007</creationdate><title>El ekzaması tedavisinde yeni bir seçenek: topikal pimekrolimus</title><author>BAŞKAN, Emel, Bülbül ; KAÇAR, Seval, Doğruk ; TUNALI, Şükran ; TURAN, Ayşegül</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-ulakbim_primary_828313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>tur</language><creationdate>2007</creationdate><topic>Administration, Topical</topic><topic>Deri ve bağ dokusu hastalıkları</topic><topic>Drug Therapy</topic><topic>Eczema</topic><topic>Egzema</topic><topic>El</topic><topic>El dermatozları</topic><topic>Hand</topic><topic>Hand Dermatoses</topic><topic>İlaç tedavisi</topic><topic>İlaç uygulama, topikal</topic><topic>pimecrolimus</topic><topic>pimekrolimus</topic><topic>Skin and connective tissue diseases</topic><topic>Terapötik</topic><topic>Therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BAŞKAN, Emel, Bülbül</creatorcontrib><creatorcontrib>KAÇAR, Seval, Doğruk</creatorcontrib><creatorcontrib>TUNALI, Şükran</creatorcontrib><creatorcontrib>TURAN, Ayşegül</creatorcontrib><collection>ULAKBIM - Mühendislik ve Temel Bilimler Veri Tabani</collection><collection>ULAKBIM - Yaşam Bilimleri Veri Tabani</collection><collection>ULAKBIM - Turk Sosyal Bilimler Veri Tabani</collection><collection>ULAKBIM - Türk Tıp Veri Tabani</collection><jtitle>Türkderm</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BAŞKAN, Emel, Bülbül</au><au>KAÇAR, Seval, Doğruk</au><au>TUNALI, Şükran</au><au>TURAN, Ayşegül</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>El ekzaması tedavisinde yeni bir seçenek: topikal pimekrolimus</atitle><jtitle>Türkderm</jtitle><date>2007</date><risdate>2007</risdate><volume>41</volume><issue>4</issue><spage>125</spage><epage>128</epage><pages>125-128</pages><issn>1019-214X</issn><abstract><![CDATA[Meslek dermatozlar&gt; aras&gt;nda en s&gt;k görülen tablo el ekzemalar&gt;d&gt;r. El ekzemalar&gt;n&gt;n kronik ve tekrarlay&gt;c&gt; seyrinden dolay&gt; tedavisi hem hasta hem de hekim için sorun teflkil etmektedir. Topikal kortikosteroidlerin uzun süreli kullan&gt;mlar&gt;na ba¤l&gt; yan etkilerinden dolay&gt; yeni tedavi aray&gt;fllar&gt; do¤mufltur. Bu çal&gt;flmam&gt;zda askomisin türevi olan ve atopik dermatit tedavisinde güvenle kullan&gt;lan topikal pimekrolimus %1 kremin el ekzemas&gt; tedavisindeki etkinli¤ini de¤erlendirmeyi amaçlad&gt;k. Gereç ve Yöntem: Plasebo kontrollü, randomize çal&gt;flmam&gt;zda bilateral el ekzemas&gt; olan toplam 25 hastan&gt;n her bir eline plasebo ve di¤er taraf&gt;na pimekrolimus %1 krem uygulat&gt;ld&gt;. Çal&gt;flman&gt;n 2., 4., 6. ve 8. haftalar&gt;nda tedaviye cevap klinik olarak de¤erlendirildi. Klinik de¤erlendirmede eritem, deskuamasyon, likenifikasyon, ödem, vezikülasyon, fissür oluflumu 0-4 aras&gt;nda skorland&gt;. Ayr&gt;ca hastalar&gt;n kafl&gt;nt&gt; de¤erlendirmesinde ayn&gt; skorlama kullan&gt;ld&gt;. Tedavi s&gt;ras&gt;nda görülen yan etkiler de kay&gt;t edildi. Hastalar 8 haftal&gt;k tedavi dönemini takiben yaklafl&gt;k 8 hafta süresince tedavisiz izlendi. Bulgular: Tedaviyi tamamlayan 9 erkek, 15 kad&gt;n hastan&gt;n yafllar&gt; 18 - 63 aras&gt;nda (ortalama yafl 35.79) de¤ifliyordu. Meslek gruplar&gt; incelendi¤inde 14'ü ev han&gt;m&gt;, 4'ü sa¤l&gt;k personeli, 3'ü ö¤retmen, 1'i polis, 1'i çiftçi ve 1'i tuhafiye malzemeleri imalatç&gt;s&gt; olarak de¤ifliyordu. Hastal&gt;k süreleri 6 ay-20 y&gt;l (ortalama 4.9 y&gt;l) aras&gt;nda idi. On üç hastada iritan kontakt dermatit, 11 hastada allerjik kontakt dermatit tan&gt;s&gt; saptand&gt;. Pimekrolimus %1 krem hastalar taraf&gt;ndan iyi tolere edilmifl ve hiçbir yan etki gözlenmemifltir. Tedavi sonu ilaç uygulanan ele ait toplam klinik skorlar plasebo uygulanan ele ait skorlar ile karfl&gt;laflt&gt;r&gt;ld&gt;¤&gt;nda anlaml&gt; bir azalma saptanm&gt;flt&gt;r (p=0.04). Sonuç: Sonuç olarak el ekzemalar&gt;n&gt;n tedavisinde topikal pimekrolimusun vezikülasyon d&gt;fl&gt;ndaki tüm belirtileri bask&gt;lamada oldukça etkili, ribaund ve tafliflaksiye neden olmayan, kullan&gt;m&gt; kolay bir tedavi seçene¤i olabilece¤i sonucuna var&gt;lm&gt;flt&gt;r. (Türkderm 2007; 41: 125-8) Hand eczema is the most common form of occupational dermatoses. Because of chronic and relapsing course, therapy is a problem for both physician and patient. New treatment alternatives have been investigated because of side effects of long-term topical corticosteroids use. In this study, we aimed to evaluate the efficacy of pimecrolimus 1% cream, an ascomisin derivative successfully used for atopic dermatitis, in the treatment of hand eczema. Material and Method: In this placebo-controlled, randomized study, pimecrolimus 1% cream was applied on one hand and placebo on the other hand of 25 patients twice daily for 8 weeks. Response to the therapy was assessed clinically at 2., 4., 6. and 8. weeks of the therapy. In the clinical assessment, erythema, desquamation, lichenification, edema, vesiculation and fissuring were scored between 0-4. Same scoring system was used also for the pruritus symptom of the patients. Side effects during the therapy were also recorded. The patients were followed for 8 additional weeks after the end of the therapy. Results: Nine male and 15 female patients with ages ranging from 18 to 63 (mean 35.79) completed the study. Of the patients, 14 were housewives, 4 were health workers, 3 were teachers, 1 was policeman, 1 was farmer and 1 was a haberdasher. The duration of disease ranged between 6 months and 20 years (mean 4.9 years). Diagnosis of irritant contact dermatitis was made in 13 patients and allergic contact dermatitis in 11 patients. Pimecrolimus 1% cream was well tolerated in all patients and no side effect was observed. The clinical score of pimecrolimus-applied hand improved significantly when compared with placebo applied hand (p=0.04). Conclusion: It is concluded that topical pimecrolimus cream appears to be an effective and easily appliable treatment alternative for all manifestations of hand eczema except for vesiculation, without any rebound and tachyphylaxis. (Turkderm 2007; 41: 125-8)]]></abstract><pub>Deri ve Zührevi Hastalıkları Derneği</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1019-214X
ispartof Türkderm, 2007, Vol.41 (4), p.125-128
issn 1019-214X
language tur
recordid cdi_ulakbim_primary_82831
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Administration, Topical
Deri ve bağ dokusu hastalıkları
Drug Therapy
Eczema
Egzema
El
El dermatozları
Hand
Hand Dermatoses
İlaç tedavisi
İlaç uygulama, topikal
pimecrolimus
pimekrolimus
Skin and connective tissue diseases
Terapötik
Therapeutics
title El ekzaması tedavisinde yeni bir seçenek: topikal pimekrolimus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T04%3A06%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-ulakbim&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=El%20ekzamas%C4%B1%20tedavisinde%20yeni%20bir%20se%C3%A7enek:%20topikal%20pimekrolimus&rft.jtitle=Tu%CC%88rkderm&rft.au=BA%C5%9EKAN,%20Emel,%20B%C3%BClb%C3%BCl&rft.date=2007&rft.volume=41&rft.issue=4&rft.spage=125&rft.epage=128&rft.pages=125-128&rft.issn=1019-214X&rft_id=info:doi/&rft_dat=%3Culakbim%3E82831%3C/ulakbim%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true